Abstracts Archive - Page 2552 of 2607 - ACR Meeting Abstracts

Abstract Number: 791 • 2012 ACR/ARHP Annual Meeting
Leg Muscle Mass Is Not Affected by Foot Pain, Structure or Function: The Framingham Foot Study
Alyssa B. Dufour¹, Marian T. Hannan², Patricia P. Katz³, Jody L. Riskowski⁴, Thomas J. Hagedorn⁵, Virginia A. Casey⁵ and Robert R. McLean¹, ¹Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA, ²Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Medicine, University of California San Francisco, San Francisco, CA, ⁴Institute for Aging Research, Hebrew SeniorLife & Harvard Medical School, Boston, MA, ⁵Institute for Aging Research, Hebrew SeniorLife, Boston, MA
Background/Purpose: While foot pain has been linked to poor outcomes, little is known about how the foot might affect physical functioning or, specifically, leg muscle…
Abstract Number: 792 • 2012 ACR/ARHP Annual Meeting
Associations of Foot Structure and Function to Low Back and Lower Extremity Pain
Jody L. Riskowski¹, Alyssa B. Dufour², Thomas J. Hagedorn³, Howard J. Hillstrom⁴, Virginia A. Casey³ and Marian T. Hannan¹, ¹Institute for Aging Research, Hebrew SeniorLife & Harvard Medical School, Boston, MA, ²Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA, ³Institute for Aging Research, Hebrew SeniorLife, Boston, MA, ⁴Rehabilitation, Hospital Special Surgery (HSS), New York, NY
Background/Purpose: Common risk factors of low back/lower extremity (LB/LE) joint pain are age, gender and body mass index (BMI), with women, older adults and overweight/obese…
Abstract Number: 753 • 2012 ACR/ARHP Annual Meeting
Progress Report On Development of Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies
Anna Tjärnlund¹, Matteo Bottai², Lisa G. Rider³, Victoria P. Werth⁴, Clarissa A. Pilkington⁵, Marianne de Visser⁶, Lars Alfredsson⁷, Anthony A Amato⁸, Richard J. Barohn⁹, Matthew H. Liang¹⁰, Jasvinder A. Singh¹¹, Frederick W. Miller³, Ingrid E. Lundberg¹² and the International Myositis Classification Criteria Project¹³, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Stockholm, Sweden, ²Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ³Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁴Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA, ⁵Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁶Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁷Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁹Department of Neurology, University of Kansas Medical Center, Kansas City, USA, Kansas City, MO, ¹⁰Dept Med/Rheum/Immun/PBB-B3, Brigham & Womens Hospital, Boston, MA, ¹¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ¹²Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ¹³Stockholm
Background/Purpose: In patients with idiopathic inflammatory myopathies (IIM) persisting muscle impairment after treatment underscores the need for improved management. Inadequate classification criteria for IIM are…
Abstract Number: 754 • 2012 ACR/ARHP Annual Meeting
The Functional Index-3 in Adult Dermatomyositis and Polymyositis: Validity and Reliability of an Outcome Measure for Muscle Endurance
Christopher Chong¹, Orla Ni Mhuircheartaigh¹, Helene Alexanderson², Tanaz A. Kermani³, Cynthia S. Crowson⁴, Abigail B. Green⁴, Ann M. Reed⁵ and Floranne C. Ernste⁶, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Dept of Neuroscience, Care Science and Society, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology, University of California Los Angeles, Los Angeles, CA, ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Although muscle fatigue is a major source of functional impairment in dermatomyositis (DM) and polymyositis (PM), few valid and reliable methods for efficient evaluation…
Abstract Number: 755 • 2012 ACR/ARHP Annual Meeting
Sifalimumab, an Anti-IFN-Alpha Monoclonal Antibody Shows Target Suppression of a Type I IFN Signature in Blood and Muscle of Dermatomyositis and Polymyositis Patients
Brandon W. Higgs¹, Wei Zhu², Chris Morehouse¹, Wendy White³, Philip Brohawn¹, Charles Le⁴, Anthony A Amato⁵, David Fiorentino⁶, Steven A. Greenberg⁵, Laura Richman¹, Warren Greth⁴, Bahija Jallal¹ and Yihong Yao³, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Science, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune, Gaithersburg, MD, ⁴Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: To assess the pharmacodynamic effects of sifalimumab, an investigational anti-IFN-alpha monoclonal antibody, in the blood and muscle of adult dermatomyositis and polymyositis patients by…
Abstract Number: 756 • 2012 ACR/ARHP Annual Meeting
Effect of B Cell Depletion Therapy with Rituximab On Myositis Associated Autoantibody Levels in Idiopathic Inflammatory Myopathy
Rohit Aggarwal¹, Chester V. Oddis², Andriy Bandos³, Danielle Goudeau⁴, Diane Koontz³, Qi Zengbiao³, Ann M. Reed⁵, Dana P. Ascherman⁶ and Marc C. Levesque⁷, ¹Rheumtology, University of Pittsburgh, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immun, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Medicine/Rheumatology, University of Miami, Miami, FL, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Myositis associated autoantibodies (MAA) in idiopathic inflammatory myopathy (IIM) demonstrate unique phenotypic features. In some autoimmune disorders, autoantibody levels correlate with disease activity and…
Abstract Number: 757 • 2012 ACR/ARHP Annual Meeting
Beneficial Role of Rapamycin in Experimental Autoimmune Myositis
Nicolas Prevel¹, Yves Allenbach², David Klatzman¹, Benoit Salomon¹ and Olivier Benveniste³, ¹UPMC Université Paris 06, UMR 7211, Paris, France, ²Internal Medicine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France, ³Internal Medecine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France
Background/Purpose: Idiopathic inflammatory myopathies are a heterogeneous group of different diseases, classified into four main categories: dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and sporadic inclusion body…
Abstract Number: 758 • 2012 ACR/ARHP Annual Meeting
Cutaneous Ulceration in Dermatomyositis: Association with MDA-5 and Interstitial Lung Disease
Neera Narang¹, Livia Casciola-Rosen², Antony Rosen², David Fiorentino³ and Lorinda Chung⁴, ¹Stanford Univ Medical Center, Stanford, CA, ²Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Rheumatology, Stanford Univ Medical Center, Palo Alto, CA
Background/Purpose: Dermatomyositis (DM) is a multisystem autoimmune disease that affects the muscles and skin and can be associated with malignancy or interstitial lung disease (ILD). …
Abstract Number: 759 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis and Fever: Results From Two Pivotal Phase 3 Trials
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin⁴, Nico Wulffraat², Gerd Horneff⁵, Riva Brik⁶, Liza McCann⁷, Huri Ozdogan², Lidia Rutkowska-Sak⁷, Rayfel Schneider¹, Yackov Berkun⁸, Inmaculada Calvo⁵, Muferet Erguven⁷, Laurence Goffin⁷, Michael Hofer⁹, Tilmann Kallinich¹⁰, Karine Lheritier¹¹, Ken Abrams¹², Andrea Stancati¹¹, D. J. Lovell¹³ and Alberto Martini¹⁴, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ²Paediatric Rheumatology International Trials Organisation (PRINTO)-Istituto Gaslini, Genova, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Pediatric Rheumatology, University Childrens Hospital, Budapest, Hungary, ⁵PRINTO, Genoa, Italy, ⁶Pediatrics, Rambam Medical Center, Haifa, Israel, ⁷Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ⁸Pediatrics, Hadassah Medical Center, Mount Scopus, Jerusalem, Israel, ⁹Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, ¹⁰Charite, University Medicine Berlin, Berlin, Germany, ¹¹Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹³Cincinnati Children's Hospital, Cincinnati, OH, ¹⁴Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH
Background/Purpose : Systemic juvenile idiopathic arthritis (sJIA) is an interleukin-1β (IL-1β)-mediated autoinflammatory disease. Canakinumab is a selective, fully human, anti-IL-1β monoclonal antibody. Two pivotal phase…
Abstract Number: 760 • 2012 ACR/ARHP Annual Meeting
Catch-up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: 2-Year Data From a Phase 3 Clinical Trial
Fabrizio De Benedetti¹, Nicolino Ruperto², Graciela Espada³, Valeria Gerloni⁴, Berit Flato⁵, Gerd Horneff⁶, Barry L. Myones⁷, Karen Onel⁸, James Frane⁹, Andrew Kenwright¹⁰, Terri H. Lipman¹¹, Kamal N. Bharucha⁹, Alberto Martini⁷ and D. J. Lovell¹², ¹Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, ³Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, ⁴Istituto Gaetano Pini, Milan, Italy, ⁵Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁶Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ⁷Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ⁸PRCSG, Cincinnati, OH, ⁹Genentech, South San Francisco, CA, ¹⁰Roche, Welwyn Garden City, United Kingdom, ¹¹University of Pennsylvania School of Nursing, Philadelphia, PA, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA), characterized by chronic arthritis associated with prominent systemic and laboratory features, also has a significant impact on the growing…
Abstract Number: 761 • 2012 ACR/ARHP Annual Meeting
Analysis of Biomarkers in Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy
Nico Wulffraat¹, Hermine Brunner², Nicolino Ruperto³, Pierre Quartier⁴, Riva Brik⁵, Liza McCann⁵, Huri Ozdogan⁵, Lidia Rutkowska-Sak⁵, Rayfel Schneider², Valeria Gerloni⁵, Liora Harel⁶, Maria Hilário², Kristin Houghton², Rik Joos⁵, Daniel Kingsbury², Arndt Brachat⁷, Stephan Bek⁷, Martin Schumacher⁷, Marie-Anne Valentin⁸, N.R Nirmala⁹, Hermann Gram⁷, Ken Abrams¹⁰, Alberto Martini¹¹ and D. J. Lovell¹², ¹PRINTO, Genoa, Italy, ²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ³Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ⁴Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ⁵Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ⁶Pediatric Rheumatology unit, Schneider Children's Medical Center, Tel Aviv University, Petach Tikvah, Israel, ⁷Novartis Institutes for Biomedical Research, Basel, Switzerland, ⁸Biomarker Development, Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Institutes for Biomedical Research, Cambridge, MA, ¹⁰Novartis Pharmaceuticals Corporation, New Jersey, ¹¹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is a severe disabling subtype of Juvenile Idiopathic Arthritis characterized by arthritis plus systemic symptoms, such as high fever,…
Abstract Number: 762 • 2012 ACR/ARHP Annual Meeting
Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis
Yukiko Kimura¹, Jennifer E. Weiss², Kathryn L. Haroldson¹, Tzielan C. Lee³, Marilynn G. Punaro⁴, Sheila K. Feitosa de Oliveira⁵, C. Egla Rabinovich⁶, Meredith P. Riebschleger⁷, Jordi Anton⁸, Peter R. Blier⁹, Valeria Gerloni¹⁰, Melissa M. Hazen¹¹, Elizabeth Kessler¹², Karen Onel¹³, Murray H. Passo¹⁴, Robert M. Rennebohm¹⁵, Carol A. Wallace¹⁶, Patricia Woo¹⁷, Nico M. Wulffraat¹⁸ and CARRAnet Investigators¹⁹, ¹Pediatric Rheumatology, JM Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ³Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁵Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁷Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI, ⁸Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, ⁹Pediatrics, Baystate Children's Hospital, Springfield, MA, ¹⁰Pediatric Rheumatology, Gaetano Pini Chair of Rheum, Milan, Italy, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ¹³Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁴Pediatrics, Medical University of South Carolina, Charleston, SC, ¹⁵Pediatric Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ¹⁶Pediatrics, Seattle Childrens Hospital, Seattle, WA, ¹⁷Division of Infection and Immunity, University College London, London, United Kingdom, ¹⁸Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Durham
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is characterized by fevers, rash and arthritis, for which IL1 and IL6 inhibitors appear to be effective. Pulmonary artery…
Abstract Number: 763 • 2012 ACR/ARHP Annual Meeting
Incidence of Selected Opportunistic Infections Among Children with Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², John Baddley³, Lang Chen⁴, Elizabeth S. Delzell⁵, Carlos Grijalva⁶, Melissa L. Mannion¹, Nivedita M. Patkar⁷, Kenneth G. Saag⁸, Kevin L. Winthrop⁹ and Jeffrey R. Curtis², ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Preventive Medicine, Vanderbilt University, Nashville, TN, ⁷Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Div Clinical Immun & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: There may be an increased risk of opportunistic infections among children with juvenile idiopathic arthritis (JIA), especially with exposure to immunosuppressant medications. No controlled…
Abstract Number: 764 • 2012 ACR/ARHP Annual Meeting
The Impact of Adalimumab On Growth in Patients with Juvenile Idiopathic Arthritis
D. J. Lovell¹, Nicolino Ruperto², Katerina Jarosova³, Dana Nemcova⁴, Veronika Vargova³, Hartmut Michels³, Elizabeth Chalom⁵, Norman Ilowite⁵, Carine Wouters⁶, Hermine Brunner⁷, Karolyn Kracht⁸, Hartmut Kupper⁹, Edward Giannini⁵, Alberto Martini¹⁰ and Neelufar Mozaffarian¹¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, ³PRINTO, Gaslini Institute, Genova, Italy, ⁴Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶PRINTO, Genoa, Italy, ⁷PRCSG, Cincinnati Children’s Hospital Medical Center, Genova, Italy, ⁸Abbott, Abbott, Abbott Park, IL, ⁹Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ¹⁰Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ¹¹Abbott, Abbott Park, IL
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) often exhibit growth impairments. Treatment with adalimumab (ADA) has been shown to be safe and effective in JIA…
Abstract Number: 765 • 2012 ACR/ARHP Annual Meeting
A Prediction Rule for the Development of Rheumatoid Arthritis: A Prospective Cohort Study of Seropositive Arthralgia Patients
Lotte van de Stadt¹, B. I. Witte², W.H. Bos¹ and Dirkjan van Schaardenburg¹, ¹Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients presenting with arthralgia and a positive test for anti-cyclic citrullinated peptide antibodies (aCCP) and/or IgM rheumatoid factor (IgM-RF) (seropositive) are at risk for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].